secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mural Oncology plc (—)
CIK:        0001971543
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036150
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mural Oncology Q4 net loss $59.5M, cash $270.9M; nemvaleukin trials on track for 1H 2025 readouts
--------------------------------------------------------------------------------

- Net loss of $59.5M for Q4 2023 includes $15.2M non-cash share-based compensation, mostly one-time spin-out charges.
- Cash and equivalents $270.9M; cash runway projected into Q4 2025.
- Phase 2 ARTISTRY-6 mucosal melanoma cohort (potentially registrational) top-line data expected 1H 2025.
- New recommended phase 2 dose for LFIV dosing (30 µg/kg) to be evaluated in ARTISTRY-6 cohort 3.
- Company intends to nominate development candidates for engineered IL-18 and IL-12 therapies in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/0000950170-24-036150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/mura-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer